$77.00
1.56% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Praxis Precision Medicines Inc Stock price

$77.00
-2.45 3.08% 1M
+37.24 93.66% 6M
+54.72 245.60% YTD
+54.03 235.22% 1Y
-218.05 73.90% 3Y
-208.00 72.98% 5Y
-208.00 72.98% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-1.22 1.56%
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Key metrics

Market capitalization $1.44b
Enterprise Value $1.08b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 670.65
P/S ratio (TTM) P/S ratio 891.37
P/B ratio (TTM) P/B ratio 3.58
Revenue growth (TTM) Revenue growth -16.93%
Revenue (TTM) Revenue $1.61m
EBIT (operating result TTM) EBIT $-164.02m
Free Cash Flow (TTM) Free Cash Flow $-98.45m
Cash position $357.03m
EPS (TTM) EPS $-10.30
P/E forward negative
P/S forward 977.60
EV/Sales forward 735.52
Short interest 7.87%
Show more

Is Praxis Precision Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Praxis Precision Medicines Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Praxis Precision Medicines Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Praxis Precision Medicines Inc forecast:

Buy
90%
Hold
10%

Financial data from Praxis Precision Medicines Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.61 1.61
17% 17%
100%
- Direct Costs 0.42 0.42
66% 66%
26%
1.18 1.18
71% 71%
73%
- Selling and Administrative Expenses 50 50
18% 18%
3,122%
- Research and Development Expense 115 115
18% 18%
7,112%
-164 -164
18% 18%
-10,161%
- Depreciation and Amortization 0.42 0.42
66% 66%
26%
EBIT (Operating Income) EBIT -164 -164
17% 17%
-10,187%
Net Profit -151 -151
10% 10%
-9,380%

In millions USD.

Don't miss a Thing! We will send you all news about Praxis Precision Medicines Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Praxis Precision Medicines Inc Stock News

Neutral
GlobeNewsWire
11 days ago
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs Praxis plans to initiate an all-DEE trial (EMERALD), inclusive of Dravet syndrome, in 1H2025 BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , ...
Neutral
Business Wire
24 days ago
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.
Neutral
GlobeNewsWire
26 days ago
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024.
More Praxis Precision Medicines Inc News

Company Profile

Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Marcio Souza
Employees 82
Founded 2015
Website www.praxismedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today